Rinat Neuroscience Corporation

Alector LLC

Pfizer Corporation

Genentech, Inc.

Wei-Hsien Ho

Arnon Rosenthal

Shu-Hui Liu

Jaume Pons

Arvind Rajpal

Pavel Strop

Patricia Culp

David L Shelton

Magdalena Grazyna Dorywalska

Phyllis L Osheroff

Flavia Mercer Pernasetti

Jan Markus Grimm

Thomas-Toan Tran

Andrew Pincetic

Helen Lam

Jeonghoon Sun

Yasmina Noubia Abdiche

Tina Schwabe

Karin Ute Jooss

Seung-Joo Lee

Sawsan Youssef

Helen Kim Cho

Ilaria Tassi

Herve Rhinn

Angie Grace Yee

Philip Ling Kong

Leonard Presta

Muhammad Abbas Alhawagri

Hua Long

Ananya Mitra

Karpagam Srinivasan

Santiago Viveros Salazar

Daniel P Bermingham

Francesca Cignarella

Klaus-Dieter Heger

David Louis Shelton

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-SIRPα antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-CD33 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Siglec-7 antibodies and methods of use thereof

Anti-SIRPa antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A4A antibodies and methods of use thereof

The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Anti-PD-1 antibodies and methods of use thereof

Anti-SIRPA antibodies and methods of use thereof

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

Antibodies specific for Trop-2 and their uses

The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.

Anti-CXCR4 antibodies and antibody-drug conjugates

Antibodies specific for TROP-2 and their uses

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.

Heterodimeric proteins and methods for producing and purifying them

Antibodies specific for trop-2 and their uses

Growing community of inventors

Belmont, CA, United States of America

Wei-Hsien Ho